| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
From the Department of Neurology (Dr. Murman, S.B. Kuo and M.C. Powell), Michigan State University, East Lansing, MI; and Department of Psychiatry and Office of the Dean (Dr. Colenda), Texas A&M University System Health Sciences Center, College Station, TX.
Address correspondence and reprint requests to Dr. Daniel L. Murman, Department of Neurology, Michigan State University, B445 Clinical Center, East Lansing, MI 48824; e-mail: murman{at}msu.edu
Objective: To compare the annual direct costs for patients with Alzheimer’s disease (AD) and no parkinsonism (AD), patients with AD and parkinsonism (AD/P), and patients with dementia with Lewy bodies (DLB). For the entire sample, the authors examined the incremental costs associated with increasing parkinsonism.
Methods: Cross-sectional comparisons of 1 year of direct costs were done. Fifteen patients met criteria for DLB, and 133 met criteria for probable AD, of whom 39 had signs of parkinsonism and 94 did not. Patients’ caregivers reported on the patient’s use of health care services, receipt of unpaid care, and comorbid medical conditions. Severity of cognitive impairment and parkinsonism were determined during patient examinations. Costs were estimated by multiplying utilization data by a unit cost for each type of care. Costs were compared after adjustment for covariates using multiple regression equations.
Results: After adjusting for important covariates, patients with AD/P or DLB had significantly higher annual direct costs than patients with AD. The average adjusted increases in costs above the AD baseline costs were $7,119 (AD/P) and $13,754 (DLB) for formal direct costs and $7,394 (AD/P) and $19,564 (DLB) for total direct costs. Models for the entire sample estimated that a 1-point increase in a parkinsonism scale would result in an annual increase of $784 in formal costs and $827 in total costs of care.
Conclusions: Patients with Alzheimer’s disease and parkinsonism or dementia with Lewy bodies have significantly higher formal and total direct costs of care than patients with Alzheimer’s disease. Signs of parkinsonism in patients with degenerative dementias are significant independent predictors of costs of care.
Received February 7, 2003. Accepted in final form June 18, 2003.
This article has been cited by other articles:
|
|
 |
|
  C. W. Zhu, N. Scarmeas, R. Torgan, M. Albert, J. Brandt, D. Blacker, M. Sano, and Y. Stern Longitudinal study of effects of patient characteristics on direct costs in Alzheimer disease Neurology, September 26, 2006; 67(6): 998 - 1005. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. W. Zhu, N. Scarmeas, R. Torgan, M. Albert, J. Brandt, D. Blacker, M. Sano, and Y. Stern Clinical features associated with costs in early AD: Baseline data from the Predictors Study Neurology, April 11, 2006; 66(7): 1021 - 1028. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. Scarmeas, M. Albert, J. Brandt, D. Blacker, G. Hadjigeorgiou, A. Papadimitriou, B. Dubois, M. Sarazin, D. Wegesin, K. Marder, et al. Motor signs predict poor outcomes in Alzheimer disease Neurology, May 24, 2005; 64(10): 1696 - 1703. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. M. Burns, J. E. Galvin, C. M. Roe, J. C. Morris, and D. W. McKeel The pathology of the substantia nigra in Alzheimer disease with extrapyramidal signs Neurology, April 26, 2005; 64(8): 1397 - 1403. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. Scarmeas, G. M. Hadjigeorgiou, A. Papadimitriou, B. Dubois, M. Sarazin, J. Brandt, M. Albert, K. Marder, K. Bell, L. S. Honig, et al. Motor signs during the course of Alzheimer disease Neurology, September 28, 2004; 63(6): 975 - 982. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
